Compass Therapeutics (CMPX) EBITDA (2018 - 2026)

Compass Therapeutics has disclosed EBITDA across 9 years of filings, most recently posting -$18.8 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$18.8 million, down 12.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$68.5 million (down 24.71% YoY), and the FY2025 annual result was -$66.4 million, down 34.99% from the prior year.
• EBITDA came in at -$18.8 million for Q1 2026 at Compass Therapeutics, down from -$15.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$7.2 million in Q1 2022 to a low of -$19.9 million in Q2 2025.
• The 5-year median for EBITDA is -$12.1 million (2022), against an average of -$12.7 million.
• Across the five-year window, EBITDA sank 102.58% in 2022 and rose 18.32% in 2023, its largest moves.
• Compass Therapeutics' EBITDA stood at -$11.3 million in 2022, then dropped by 15.04% to -$12.9 million in 2023, then declined by 18.23% to -$15.3 million in 2024, then retreated by 2.62% to -$15.7 million in 2025, then slipped by 19.39% to -$18.8 million in 2026.
• The last three EBITDA figures came in at -$18.8 million (Q1 2026), -$15.7 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.